Inhibition of neointima formation after experimental coronary artery stenting -: A new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost
Inhibition of neointima formation after experimental coronary artery stenting -: A new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost
复制标题
DOI：
10.1161/01.cir.101.12.1453
复制
发表时间：
2000-03-28
期刊：
影响因子：
37.8
通讯作者：
Schömig, A
中科院分区：
文献类型：
--
作者：
Alt, E;Haehnel, I;Schömig, A
背景-为了使急性支架血栓形成和再狭窄的发展最小化，已经提出用可生物降解和不可生物降解的聚合物涂覆的支架作为缓释药物载体。方法和结果-在绵羊和猪模型中，我们检测了冠状动脉Palmaz-Schatz支架标准和高压植入后的血管反应，支架上涂有10 μ m的聚乳酸层（MW 30 kDa）释放重组聚乙二醇（r-PEG）-水蛭素和前列环素类似物伊洛前列素，这两种药物具有抗血栓形成和潜在的抗增殖作用。研究观察时间为28天。在相应的支架组之间，未观察到植入前和植入后植入参数的差异。形态计量学分析表明，涂层与更大的管腔直径相关，平均再狭窄面积减少22.9%（P
Background-To minimize acute stent thrombosis and development of restenosis, stents coated with biodegradable and nonbiodegradable polymers have been proposed to serve as sustained-release drug carriers,Methods and Results-In both a sheep and a pig model, we examined the vascular response to standard and high-pressure implantation of coronary Palmaz-Schatz stents coated with a 10-mu m layer of polylactic acid (MW 30 kDa) releasing recombinant polyethylene glycol (r-PEG)-hirudin and the prostacyclin analogue iloprost, both drugs with antithrombotic and potentially antiproliferative effects. Study observation time was 28 days. Between the corresponding stent groups, no differences were observed with regard to preplacement and postplacement implantation parameters. The morphometric analysis demonstrated that the coating was associated with a greater lumen diameter through a reduction in the mean restenosis area by 22.9% (P